2
results found
Background: Among F8 mutation types, main determinants of inhibitor development after replacement therapy in Hemophilia A, nonsense mutations display wide variation in the associated risk. Molecular m...
F8 PTCs
Hemophilia A
translational readthrough
inhibitory antibody
peptide MHCII affinity
personalized medicine
Background: Despite therapeutic advances, important gaps persist in hemophilia care within public healthcare systems in middle-income countries. In Brazil, universal access to prophylaxis is ensured t...
Hemophilia A
Hemophilia B
Needs Assessment
Medication adherence
Delphi Technique
Brazil
SinoXiv